-SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Ther...
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“...
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced it has signed definitive partnership agreements with Zydus Lifescienc...
Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on devel...
Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to captu...
Recludix Pharma, a leader in the discovery of inhibitors of challenging targets for inflammatory disease, today announced that the company has nominated ...
Nxera Pharma Co., Ltd. announces that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly a...
Danaher has entered a partnership with AstraZeneca to scale precision medicine, including developing the next generation of AI-powe...
- Agreement grants Astellas exclusive worldwide rights (excluding China's mainland, Hong Kong, Macao and Taiwan region) to develop and commercialize XNW2...
Exploring use of Altamira’s RNA nanoparticles in conjunction with circular RNA payloads Project collaboration partner will have option to negoti...
Liv Hospital and Istinye University have signed a comprehensive collaboration protocol with the University of Pennsylvania’s Perelman School of Medic...
The strategic collaboration with Broad Clinical Labs will explore and develop applications using Roche’s SBX sequencing technology1, with an init...
Partnership designed to expand QIAGEN’s leadership in oncology-focused digital PCR assays, advancing QIAcuity as the platform of choice for can...
Astellas Pharma Inc. (TSE: 4503) and Pfizer Inc. (NYSE: PFE) announced compelling five-year overall survival (OS) results from the open-label exten...
© 2025 Biopharma Boardroom. All Rights Reserved.
